Clinical Trials Logo

Filter by:
NCT ID: NCT04699084 Completed - Postoperative Pain Clinical Trials

The Evaluation of Mozart Music on Pain and Respiratory Rate After Thyroidectomy

Start date: February 20, 2018
Phase: N/A
Study type: Interventional

To investigate the effect of Mozart music on postoperative pain and physiological parameters in patients after total thyroidectomy.

NCT ID: NCT04694287 Completed - Clinical trials for Dialysis Access Malfunction

Volume Flow Assessment to Optimize Angioplasty of Dysfunctional Dialysis Access

VOLAII
Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

This is a multicenter, prospective study investigating a new concept of intra-procedural percutaneous duplex ultrasound (DUS) volume flow-guided balloon angioplasty for the quantification and optimization of endovascular treatment outcomes of dysfunctional autologous arteriovenous fistulae (AVF).

NCT ID: NCT04688775 Completed - Clinical trials for Cluster Headache, Episodic

Eptinezumab in Participants With Episodic Cluster Headache

ALLEVIATE
Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

NCT ID: NCT04687072 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

NCT ID: NCT04680949 Completed - Covid19 Clinical Trials

suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19

SAVE-MORE
Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by the ordinal scale of the 11-point World Health Organization (WHO) clinical progression scale (CPS).

NCT ID: NCT04673604 Completed - Glaucoma Clinical Trials

From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy

Start date: May 6, 2018
Phase: N/A
Study type: Interventional

There is a lack of evidence on the impact of switching from a combined preserved anti-glaucoma regimen to a preservative-free (PF) one, while employing sufficiently robust OSD metrics. The investigators have therefore carried out a single center, prospective, crossover investigation to compare the 6-month effect of switching well controlled open-angle glaucoma patients with at least moderate glaucoma therapy-related ocular surface disease from preserved to triple preservative-free therapy with and without cyclosporine 0.1% dosed in the evening.

NCT ID: NCT04672941 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Start date: February 16, 2021
Phase:
Study type: Observational

The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics.

NCT ID: NCT04665895 Completed - Asthma Clinical Trials

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma

ANASSA-PD
Start date: December 9, 2020
Phase: Phase 3
Study type: Interventional

Τherapeutic equivalence, randomized, multiple-dose, placebo-controlled, observer-blind, parallel group design consisting of a 2-week run-in period followed by a 4-week treatment period with Fluticasone propionate 100 mcg/ blister oral inhalation powder/Respirent Pharmaceuticals (Test) or FLOVENT DISKUS® 100mcg blister oral inhalation powder (Reference) or placebo.

NCT ID: NCT04657445 Completed - Clinical trials for Olfactory and Taste Dysfunction in SARS-CoV2 Infection

EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY

Start date: November 17, 2020
Phase:
Study type: Observational

This is an observational data and recording study. The aim of our study is to investigate the effect of SARS-COV2 infection on patients' sense of smell and taste, through quality control measurements using optic analogue scale (VAS) in hospitalized and in home-quarantined patients.

NCT ID: NCT04655638 Completed - Covid19 Clinical Trials

HFNT vs. COT in COVID-19

COVID-HIGH
Start date: February 10, 2021
Phase: N/A
Study type: Interventional

The aim of this unblinded parallel-group randomized multicenter clinical trial is to compare the clinical effectiveness of high flow nasal therapy (HFNT) with conventional oxygen therapy (COT) in patients with confirmed COVID-19 related acute hypoxemic respiratory failure.